TG makes case for umbralisib as safer lymphoma option

Bolstering support for what could be the third PI3Kδ inhibitor to gain FDA approval, TG Therapeutics said umbralisib met the primary endpoint in a second lymphoma indication in the Phase IIb UNITY-NHL trial.

TG Therapeutics Inc. (NASDAQ:TGTX) gained $1.02 (18%) to $6.80 Monday after reporting that umbralisib led to a 40-50% overall response rate (ORR), as determined by an independent review committee, in UNITY-NHL’s registration-directed cohort of relapsed or refractory follicular lymphoma patients in a third-line setting...